New drug aims to clear painful hand and foot pustules
NCT ID NCT03633396
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This phase 2 trial tested a monthly injection called imsidolimab (ANB019) in 59 adults with palmoplantar pustulosis, a chronic skin condition causing painful, pus-filled blisters on the palms and soles. The study compared the drug to a placebo to see if it could reduce the severity of the pustules and scaling. Researchers also monitored safety and side effects over 24 weeks.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
imsidolimab (ANB019)
What this could lead to
If it works, this could point toward a new treatment option for palmoplantar pustulosis, a chronic skin condition causing painful pustules on hands and feet.
What could go wrong
This is a small, early-phase trial with only 59 participants. Results may not apply to everyone, and the drug may not prove effective or safe in larger studies.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PALMOPLANTAR PUSTULOSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Investigational Site
Birmingham, Alabama, 35233, United States
-
Investigational Site
Phoenix, Arizona, 85032, United States
-
Investigational Site
Encino, California, 91436, United States
-
Investigational Site
Santa Monica, California, 90405, United States
-
Investigational Site
Fort Lauderdale, Florida, 33316, United States
-
Investigational Site
Miami, Florida, 33155, United States
-
Investigational Site
Pembroke Pines, Florida, 33028, United States
-
Investigational Site
Tampa, Florida, 33607, United States
-
Investigational Site
Indianapolis, Indiana, 46250, United States
-
Investigational Site
Plainfield, Indiana, 46168, United States
-
Investigational Site
Overland Park, Kansas, 66215, United States
-
Investigational Site
Ann Arbor, Michigan, 48109, United States
-
Investigational Site
St Louis, Missouri, 63110, United States
-
Investigational Site
St Louis, Missouri, 63117, United States
-
Investigational Site
Wilmington, North Carolina, 28405, United States
-
Investigational Site
Columbus, Ohio, 43230, United States
-
Investigational Site
Norman, Oklahoma, 73071, United States
-
Investigational Site
Portland, Oregon, 97239, United States
-
Investigational Site
Dallas, Texas, 75230, United States
-
Investigational Site
Surrey, British Columbia, Canada
-
Investigational Site
Greater Sudbury, Ontario, Canada
-
Investigational Site
Markham, Ontario, Canada
-
Investigational Site
Drummondville, Quebec, Canada
-
Investigational Site
Montreal, Quebec, Canada
-
Investigational Site
Bad Bentheim, 48455, Germany
-
Investigational Site
Berlin, 10117, Germany
-
Investigational Site
Berlin, 10789, Germany
-
Investigational Site
Bonn, 53127, Germany
-
Investigational Site
Hamburg, 20253, Germany
-
Investigational Site
Hamburg, 22391, Germany
-
Investigational Site
Schwerin, 19055, Germany
-
Investigational Site
Gdansk, 80-546, Poland
-
Investigational Site
Katowice, 40-611, Poland
-
Investigational Site
Lodz, 90-265, Poland
-
Investigational Site
Olsztyn, 10-229, Poland
-
Investigational Site
Ostrowiec Świętokrzyski, 27-400, Poland
-
Investigational Site
Rzeszów, 35-055, Poland
-
Investigational Site
Szczecin, 70-332, Poland
-
Investigational Site
Wroclaw, 50-566, Poland